Form 4: Neurocrine Biosciences CRO Executes Stock Option Plan
Statement of Changes in Beneficial Ownership
Chief Regulatory Officer Ingrid Delaet exercised and sold 2,261 shares of Neurocrine Biosciences common stock via a 10b5-1 plan.
Summary
- Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options for 2,261 shares at a price of $79.02.
- Following the exercise, the shares were sold at an average price of $156.71.
- The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2026.
- The reporting person's total beneficial ownership in the company is now 16,225 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-established 10b5-1 trading plan, which is a common and compliant method for executive stock liquidation.
Positives
- The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.
Negatives
- The transaction represents a divestment of equity by a key member of the executive leadership team.
Risks
- Executive stock sales can sometimes be perceived negatively by the market as a signal of management's view on current valuation.
Future Outlook
No specific forward-looking guidance regarding company operations was provided in this filing.
Management Comments
- The filing notes that the disposition was effected by a broker pursuant to a Rule 10b5-1 trading plan.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and is generally viewed as neutral by the investment community.
Comparison to Industry Standards
- The use of 10b5-1 plans is the industry standard for executives to avoid potential conflicts of interest regarding insider trading regulations.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the executive's total holdings.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 01/31/2022 | Original grant date of the stock options. |
| 02/27/2026 | Date the Rule 10b5-1 trading plan was adopted. |
| 05/29/2026 | Date of the stock option exercise and subsequent sale. |
| 06/02/2026 | Date the Form 4 was filed with the SEC. |
Keywords
NBIX, Neurocrine Biosciences, Insider Trading, Form 4, Stock Option Exercise, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.